Announcement • Jan 14
Epiphany Technology Acquisition Corp.(NasdaqCM:EPHY) dropped from NASDAQ Composite Index Epiphany Technology Acquisition Corp. has been dropped from NASDAQ Composite Index . Board Change • Dec 31
High number of new and inexperienced directors There are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. 2 experienced directors. No highly experienced directors. Co-CEO, CFO & Director Peter Bell is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Sep 24
Epiphany Technology Acquisition Corp. Appoints Board of Directors Effective September 16, 2022, the board of directors of Epiphany Technology Acquisition Corp. approved an increase in the size of the Board from seven (7) directors to eleven (11) directors and elected Ross Haghighat, Stephen Sherwin, Louis Lange and Ronald Eastman as members of the Board to fill the vacancies created by the increase. The Board determined that each Messrs. Stephen Sherwin, Louis Lange and Ronald Eastman is an “independent director” as defined in the Nasdaq listing standards and applicable rules of the Securities and Exchange Commission. Ross Haghighat has served as Chief Executive Officer, Chief Financial Officer and a Director of BioPlus Acquisition Corp. since December 2021. Mr. Haghighat is the founding partner at Jasper Capital Partners and Chairman of Triton Systems Inc. Mr. Haghighat has been a founder, co-founder, and board member of more than a dozen private and public technology companies in the US, Europe, China and Australia. During Mr. Haghighat’s expansive career as an operator, he generated billions in shareholder value through his roles transforming companies from early-stage technology firms to successful corporations, as well as integrated divisions of Fortune 500 companies. From 1994 to 2001, Mr. Haghighat co-founded and led CoreTek Inc. Mr. Haghighat currently serves on the Board of Directors at Chinook Therapeutics Inc., where Mr. Haghighat is Chairman of the Transaction Committee; CITIC Capital Acquisition Corp., where Mr. Haghighat also serves as Chair of the Audit Committee of Fluence Corporation Ltd., where Mr. Haghighat serves as Vice Chairman; Angel Medical Systems Inc., where Mr. Haghighat serves as Lead Director and FRX Polymers Inc., where Mr. Haghighat serves as Chairman. Mr. Haghighat received a Bachelor of Science in Advanced Materials Engineering from Rutgers University and Master of Science in Organometalic Chemistry from Rutgers University, as well as an MBA from Boston College — Wallace E Carroll School of Management. Mr. Haghighat is well qualified to serve on the Board due to his extensive operating, investing and board experience in the biotechnology industry. Ronald Eastman Since December 2021, Ronald Eastman has served as Vice Chairman of BioPlus Acquisition Corp. Mr. Eastman has over 40 years of experience in building and leading both publicly-traded and private healthcare businesses. Mr. Eastman is currently a Senior Advisor of EW Healthcare Partners (EW), where he previously served for 15 years as Managing Director of multiple funds before transitioning to Senior Advisor in 2021. Mr. Eastman led and served on the Board of Directors of EW’s investments in ProteinSimple Inc. (acquired by Bio-Techne Corporation), Corium Inc. (acquired by Gurnet Point Capital), and Open Monoclonal Technology Inc. (acquired by Ligand Pharmaceuticals Inc.). He also currently serves on the Board of Directors of EW portfolio company Suneva Medical Inc. Mr. Eastman began his career at American Cyanamid Company, which was acquired by American Home Products (now Pfizer Inc.), where Mr. Eastman spent 15 years managing various pharmaceutical products, divisions, and subsidiaries in the U.S. and overseas. Later as CEO of Geron Corporation, Mr. Eastman led the company’s growth from a venture-backed start-up to a publicly traded pioneer in the fields of regenerative medicine and cancer. As CEO of Rinat Neuroscience Corporation with the support of EW in late 2001, Mr. Eastman led the effort to build the first company dedicated to discovering and developing large molecule drugs for treating nervous system disorders. Rinat Neuroscience was acquired by Pfizer Inc. in 2006. Mr. Eastman has also previously served as a board member of Revance Therapeutics Inc., the Biotechnology Innovation Organization, and as a Trustee of the Buck Institute for Research on Aging. Mr. Eastman has a Bachelor of Arts degree from Williams College and a Master of Business Administration degree from Columbia University. Mr. Eastman is well qualified to serve on the Board due to his extensive operating, investing and board experience in the biotechnology industry. 
